Efficacy analysis of netupitan/palonosetron in preventing nausea and vomiting caused by pre-treatment chemotherapy before transplantations
10.3969/j.issn.1671-8348.2025.06.011
- VernacularTitle:奈妥匹坦帕洛诺司琼预防移植前预处理化疗所致恶心呕吐的疗效分析
- Author:
Xiaoqing CHEN
1
;
Zhigang LIU
;
Jie JI
;
Qiuhui WU
;
Juan XU
;
Pu KUANG
;
Ting NIU
Author Information
1. 四川大学华西医院血液科/层流研究病房,成都 610041;眉山市人民医院血液科,四川 眉山 620010
- Keywords:
netupitant/palonosetron;
chemotherapy;
nausea and vomiting;
hematopoietic stem cell transplantation;
pretreatment
- From:
Chongqing Medicine
2025;54(6):1339-1344,1350
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the effectiveness and safety of netupitant/palonosetron in the treat-ment of chemotherapy-induced nausea and vomiting(CINV)in hematologic tumor patients undergoing autol-ogous and allogeneic stem cell transplantation.Methods Adult hematologic tumor patients who received net-upitant/palonosetron to prevent chemotherapy-induced nausea and vomiting CINV during pre-transplant chemotherapy at West China Hospital of Sichuan University from January to September 2022 were collected.On the first and third day of pre-transplant chemotherapy,netupitant/palonosetron was orally administered one hour before the infusion of pre-transplant chemotherapy drugs,for a total of two doses.The nausea and CINV status of the patients from the start of pre-transplant chemotherapy to 7 days after stem cell infusion were recorded.Results As a result,a total of 125 patients with hematological tumors were included,and the complete remission rates during pre-treatment chemotherapy were 72.8%,80.0%and 66.4%in the acute phase,delayed phase,and total phase,respectively.The rates of no vomiting were 89.6%,92.0%and 72.8%,respectively.The rates of no rescue medication were 95.2%,93.6%and 73.6%,respectively.The complete remission rate of 33 plasma cell tumors and 46 leukemia and myelodysplastic syndrome patients exceeded 70%,and the complete remission rate of 46 lymphoma patients exceeded 90%.The complete response rate in the delayed phase of the pre-treatment CHiGCB regimen(chidamide+busulfan+gemcitabine+cladribine)was 93.5%,which was higher than the complete response rate of the BenMel regimen(bendamustine+mel-phalan)(72.7%)and the CHiFAB regimen(chidamide+busulfan+fludarabine+cytarabine)(71.7%).The complete remission rate during the follow-up period of the CHiGCB regimen was 91.3%,which was higher than that of the CHiFAB regimen(65.2%),with the statistically significance(P<0.05).Conclusion Netu-pitant/palonosetron can effectively control CINV in patients undergoing autologous or allogeneic hematopoiet-ic stem cell transplantation for hematologic tumors.
